Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial
Antonin Lévy(Inserm), Éric Deutsch(Inserm), C. Lemanski, David Malka(Inserm), Thierry Conroy(Inserm), D. Azria(Inserm), Jean‐Pierre Pignon(Inserm), Laurent Miglianico(Canadian Partnership Against Cancer), Isabelle Martel‐Lafay(Centre Léon Bérard), Julie Leclercq(Institut Gustave Roussy), Béata Juzyna(UniCancer Group), Anne Delarochefordiere(Institut Curie), Emmanuel Rio(Institut de Cancérologie de l'Ouest), Patrick Ezra(Institut Gustave Roussy), Katty Malekzadeh(Institut Gustave Roussy), Y. Bécouarn
Cited by 38
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|1.9k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k